Search
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] Vutrisiran was approved by the FDA in June 2022. … [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met).
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalThe development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin
Eteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen was the first treatment for DMD approved by the FDA.[A244925] … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that
Talmapimod
go.drugbank.com/drugs/DB05412InvestigationalTalmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Ezogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnFDA approved in June 10, 2011 under the name of ezogabine.
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalFood and Drug Administration (FDA) on 18 March 2010.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was approved for use by the FDA in August, 2007.